SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 14, 2004
Progenics Pharmaceuticals, Inc.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
---------------------------- ----------------- ---------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
-----------------
----------------------------------------------------------------
(Former name or former address, if changed since last report.)
Section 8 - Other Events
Item 8.01 Other Events
Progenics announced the appointment of Alton B. Kremer,
M.D., Ph.D. to Vice President, Clinical Research, a
newly created position in the Company. Dr. Kremer will
be responsible for medical aspects of the Company's
clinical trials.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statement and Exhibits
(c) the following exhibits are filed with this report
Exhibit Number Description
99.1 Press release dated October 14, 2004
----------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ ROBERT A. MCKINNEY
-------------------------------------------
Robert A. McKinney
Vice President, Finance & Operations
Date: October 14, 2004